<DOC>
	<DOCNO>NCT00302380</DOCNO>
	<brief_summary>The primary objective study evaluate Binding Potential subject ADHD adult without ADHD : intent demonstrate C-11 Altropane PET use differentiate adult ADHD healthy control subject .</brief_summary>
	<brief_title>An Open Label Phase I/II Study Safety Dopamine Transporter Binding Properties C-11 Altropane Normal Human Subjects Subjects With ADHD</brief_title>
	<detailed_description>This protocol seek replicate extend investigation DAT binding adult ADHD specific aim : 1 . To examine dopamine transporter ( DAT ) receptor bind potential adult ADHD , use PET scan 11C altropane ligand . We hypothesize compare adult without ADHD , adult ADHD great DAT binding account psychiatric comorbidity age . 2 . To examine relationship DAT binding clinical feature ADHD . We hypothesize DAT bind positively correlate ) severity ADHD symptom b ) neuropsychological interpersonal dysfunction . 3 . To examine relationship DAT binding genetic risk factor . We hypothesize DAT bind specifically associate homozygosity DAT ( 480 ) gene adult ADHD ADHD-associated genetic marker ( e.g. , DRD4-7 , D2 , DBH ) .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<criteria>1 . Signed write informed consent participate study . 2 . Age : 18 55 3 . If female , nonpregnant , nonnursing negative serum pregnancy test use adequate form birth control . 4 . Supine stand blood pressure within range 110/60 150/90 mmHg . 5 . Heart rate , rest 5 minute , within range 4690 beats/min . 6 . Subjects within 20 % ideal weight height 7 . Right hand 8 . Diagnosis DSMIV ADHD ( current ) , manifest clinical evaluation confirm structure interview ( ADHD study subject ) . 9 . Subjects without diagnosis DSMIV ADHD ( lifetime ) , manifest clinical evaluation confirm structure interview ( control study subject ) . 1 . Diagnosis psychotic disorder , bipolar disorder , severe depression , severe anxiety , Autism . Subjects mild mood , oppositional , conduct , anxiety disorder may permit participate consider appropriate investigator 2 . Scores Baseline Scales : Hamilton Depression Scale &gt; 17 ( possible 67 21item scale ) ( Hamilton 1960 ) Beck Depression Inventory &gt; 19 ( possible 63 21item scale ) ( Beck , Ward et al . 1961 ) Hamilton Anxiety Scale &gt; 21 ( possible 56 14item scale ) ( Hamilton 1959 ) 3 . History head trauma loss consciousness , organic brain disorder , seizure , neurosurgical intervention . 4 . Any clinically significant chronic medical condition , judgement investigator . 5 . Mental impairment evidence I.Q . &lt; 75 . 6 . Subject must investigational drug least 4 week prior start study . 7 . Exposure dopamine receptor antagonist , include stimulant medication ( e.g . methylphenidate ) buproprion within previous three ( 3 ) month start study . 8 . Exposure nonstimulant ADHD medication ( e.g . atomoxetine ) within previous 4 week start study . 9 . Exposure radiopharmaceutical within four ( 4 ) week prior PET scan . 10 . Subjects receive psychotropic medication . 11 . Any clinically significant abnormality screen laboratory test , vital sign , 12lead ECG , outside normal limit . 12 . Any woman childbearing potential seek become pregnant suspect may pregnant . 13 . Subjects know recent history ( within past six ( 6 ) month ) illicit drug alcohol dependence .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>